Results 281 to 290 of about 88,489 (340)

A simplified approach for diagnosing heart failure with preserved ejection fraction by assessing the left atrium and natriuretic peptides

open access: yesEuropean Journal of Heart Failure, EarlyView.
Applying a simplified left atrial/natriuretic peptide (LA/NP) approach by combining enlarged LA volume indexed for height2 or elevated (N‐terminal pro) B‐type natriuretic peptide [(NT‐pro)BNP], using different cut‐off values for sinus rhythm (SR) and atrial fibrillation (AF) history.
Jerremy Weerts   +13 more
wiley   +1 more source

Minimization or withdrawal of oral pharmacotherapy in chronic heart failure patients with improved myocardial function: A systematic review

open access: yesEuropean Journal of Heart Failure, EarlyView.
This systematic review included seven studies that reported the outcomes of minimization or withdrawal of oral pharmacotherapy in chronic heart failure (HF) patients with improved myocardial function. There is a dearth of existing evidence, which supports only loop diuretic withdrawal and possibly carvedilol monotherapy.
Yuxiang Luo   +8 more
wiley   +1 more source

Syntheses and Biological Activities of Selenium Analogs of .ALPHA.-Rat Atrial Natriuretic Peptide.

open access: bronze, 1993
Takaki Koide   +5 more
openalex   +2 more sources

Clinical and plasma proteomic characterization of heart failure with supranormal left ventricular ejection fraction: An emerging entity of heart failure

open access: yesEuropean Journal of Heart Failure, EarlyView.
Heart failure (HF) with supranormal ejection fraction (HFsnEF) is an unnoticed but emerging entity in HF. This study showed that HFsnEF carries a similarly increased cardiovascular risk as HF with reduced ejection fraction (HFrEF) and distinct structural and proteomic characteristics from HFrEF, warranting a further comprehensive understanding and ...
Yasuhiko Sakata   +19 more
wiley   +1 more source

<b>PUTATIVE LIGAND-BINDING SITES OF THE TYPE C ATRIAL NATRIURETIC PEPTIDE </b><b>RECEPTOR </b>

open access: bronze, 1993
Akihiro Higuchi   +4 more
openalex   +2 more sources

Ferric carboxymaltose assessment of morbidity and mortality in patients with iron deficiency and chronic heart failure (FAIR‐HF2‐DZHK05) trial: Baseline characteristics and comparison to other relevant clinical trials

open access: yesEuropean Journal of Heart Failure, EarlyView.
Differences in baseline characteristics between major trials of intravenous (IV) iron therapy in heart failure. LVEF, left ventricular ejection fraction; SGLT2, sodium–glucose cotransporter 2. Aims Prior randomized trials have reported conflicting evidence regarding the efficacy of intravenous (IV) iron in patients with heart failure with reduced ...
Stefan D. Anker   +44 more
wiley   +1 more source

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status. BMI, body mass index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.
Jawad H. Butt   +16 more
wiley   +1 more source

Heart failure in patients with a systemic right ventricle: A multicentre study with long‐term follow‐up

open access: yesEuropean Journal of Heart Failure, EarlyView.
Risk of heart failure hospitalization in patients with a systemic right ventricle. AF, atrial fibrillation; AtrSO, atrial switch operation; ccTGA, congenitally corrected transposition of the great arteries; D‐TGA, dextro‐transposition of the great arteries; ECG, electrocardiogram; HF, heart failure; HR, hazard ratio; NYHA, New York Heart Association ...
Mohammad Mostafa Ansari Ramandi   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy